A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-Controlled, Dose Escalation Study to Assess Safety, Efficacy and Pharmacokinetics of GMA301 in Subjects With Pulmonary Arterial Hypertension

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04503733
• Other study ID #: GETA_MAD_01
• Status: Recruiting
• Phase: Phase 1
• Start date: October 22, 2020
• Est. completion date: June 10, 2023

Study information

• Verified date: December 2021
• Source: Gmax Biopharm LLC.
• Contact: Jianjun Wu
• Phone: +8618358737112
• Email: jianjunwu[@]gmaxbiopharm.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Randomized, Placebo-Controlled, Double-blind, Dose Escalation Study to Assess Safety, Efficacy and Pharmacokinetics of GMA301 Injection in Subjects with Pulmonary Arterial Hypertension

Description:

Drug: Q4W GMA301 IV injections (300 mg) Drug: Q4W GMA301 IV injections (600 mg) Drug: Q4W GMA301 IV injections (1000 mg) Drug: Q4W GMA301 IV injections (1800 mg) Other: Q4W placebo IV injections

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: June 10, 2023
• Est. primary completion date: October 26, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria

Subjects must meet all of the following criteria:

1. Male or female, aged 18 to 75 years inclusive

2. WHO Group 1 PAH related to one of the following conditions:

1. Idiopathic

2. Heritable

3. Drugs or toxins-induced

4. Associated with connective tissue disease

5. Associated with congenital heart disease if subjects underwent surgical correction more than 12 months before Screening

3. Symptoms due to PAH are consistent with WHO functional class II- III

4. Have not taken endothelin receptor antagonists (ERAs) within 3 months before Randomization

5. Has been taking at least one oral PAH targeted drug that has been approved by local guidelines for at least 3 months before Screening with stable dosage and the disease did not worsen during this period per Investigator's judgment

6. Right heart catheterization (RHC) result meets below criteria when Screening:

1. Mean pulmonary arterial pressure (PAP) =25 mmHg

2. Pulmonary vascular resistance (PVR) >3 Woods units

3. PA wedge pressure (PAWP) =15 mmHg

If a subject has undergone RHC within 3 months before Screening, the waveform results will serve as baseline data only if they meet the entry criteria and the RHC at Screening will not be repeated. In case PAWP cannot be well measured during RHC, left ventricular end diastolic pressure will be tested by left heart catheterization.

7. Has a six-minute walk test (6MWT) with distance between 150 to 450 meters at Screening

8. The dosage of digitalis drugs or L-arginine supplementation must be stable for at least 1 month before Screening, if applicable.

9. No new use of an IV diuretic, cardiotonic (positive inotropic agents), or vasoactive drug within 30 days before Screening

10. Both male and female subjects agree to use 2 medically acceptable methods of contraception (Appendix 4) throughout the entire study period from informed consent signing to 90 days after last dose, if the possibility of conception exists. Medically acceptable methods of contraception include oral, implantable, or injectable contraceptives (starting 2 months before dosing); diaphragm with vaginal spermicide; intrauterine device; condom and partner using vaginal spermicide; and surgical sterilization (6 months after surgery). Women who are surgically sterile or those who are postmenopausal for at least 2 years are not considered to be of childbearing potential. Eligible male and female subjects must agree not to participate in a conception process (i.e. active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization) during the study and for 90 days after the last dose of study drug.

11. Body weight no less than 40 kg at Screening

12. Able to understand and willing to sign the Informed Consent Form (ICF) and comply with the study procedures.

Exclusion Criteria

Subjects who me et any of the following criteria will not be allowed to participate in this study:

1. Diagnosed with WHO Group II, III, IV, V of PH

2. Use of calcium channel blockers within 1 month prior to Screening

3. Systolic blood pressure (SBP) >160 mmHg or diastolic blood pressure (DBP) >100 mmHg at Screening

4. SBP <90 mmHg at Screening

5. Pulmonary function test: FEV1 <60% of predicted, TLC <60% of predicted, DLCO <60% of predicted

6. History of pulmonary embolism as judged by the Investigator

7. Uncontrolled sleep apnea at the discretion of the Investigator

8. Limited full participation in the 6MWT due to arthritic, neuromuscular, vascular or other diseases unrelated to PAH

9. History of acute cardiovascular and/or cerebrovascular events within 6 months before Screening

10. Echocardiogram (ECHO) demonstrating at least one of the following at Screening:

1. LVEF <50%

2. Mean end-diastolic left ventricular septal and posterior wall thickness of >12 mm

3. Left atrial (LA) area on apical 4 chamber view >20 cm2

4. LA volume >55 mL

5. LA volume index >34 mL/m2

6. Significant valvular heart disease including moderate or severe mitral or aortic stenosis with an aortic valve area <1.0 cm2 or mitral valve area <1.5 cm2, greater than moderate aortic or mitral regurgitation, greater than moderate tricuspid or pulmonic stenosis

11. Restrictive, dilated or hypertrophic cardiomyopathy or constrictive pericarditis

12. Using non-oral prostacyclin when Screening

13. Laboratory parameters during Screening:

1. Baseline aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =2 times the upper limit of normal (ULN) or total bilirubin =1.5 times ULN

2. Estimated glomerular filtration rate (eGFR) <60 mL/min by Cockcroft-Gault formula

Online calculation available from https://www.kidney.org/professionals/KDOQI/gfr_calculatorCoc

Cockcroft-Gault formula (1973):

Male: CCr=((l40-Age) × Weight)/(72×SCr)

Female: CCr={((l40-Age) × Weight)/(72×SCr)}× 0.85

CCr (creatinine clearance rate) = mL/min

Age = year

Weight = Kg

SCr (serum creatinine) = mg/dL

3. Hemoglobin concentration =100 g/L at Screening

14. QTc interval by Fridericia's criteria (QTcF) =500 msec at Screening

15. Malignancy within 5 years before Screening visit (with the exception of localized non-metastatic basal cell carcinoma of the skin, non-metastatic carcinoma of the prostate or in-situ carcinoma of the cervix excised with curative results)

16. Alcohol or drug abuse within 1 year before Screening

17. A psychiatric, addictive or other disorder that compromises the ability to give informed consent for participating in this study

18. History of organ transplantation

19. Pregnant or nursing females

20. History of HIV

21. Positive hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), or HIV antibody (HIV-ab)

22. Enrolled in another interventional study within 30 days before Screening

23. Any condition that, in the opinion of the Investigator, prevents a potential subject from safely participating in the study

24. Start a new exercise program or participate in any unusually strenuous physical exertion within 6 weeks prior to Screening.

Related Conditions & MeSH terms

• Familial Primary Pulmonary Hypertension
• Hypertension
• Pulmonary Arterial Hypertension

Intervention

Drug:
• Q4W GMA301 IV injections (300 mg)
Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
• Q4W GMA301 IV injections (600 mg)
Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
• Q4W GMA301 IV injections (1000 mg)
Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
• Q4W GMA301 IV injections (1800 mg)
Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.

Other:
• Q4W placebo IV injections
Placebo is indistinguishable from GMA301.

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital - Dongcheng District	Beijing
China	Xiangya Hospital, Central South University	Changsha
China	The First Affiliated Hospital of Chongqing Medical University	Chongqing
China	Guangdong General Hospital	Guangzhou
China	Shanghai Pulmonary Hospital	Shanghai
China	The First Affiliated Hospital of Xi'an Jiaotong University	Xian
United States	Brigham and Women's Hospital	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Gmax Biopharm LLC.

Countries where clinical trial is conducted

United States,  China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Changes in REVEAL 2.0 risk score at Week 12 compared with baseline	Calculated risk scores can range from 0 (lowest risk) to 23 (highest risk).	Baseline to Week 12
Primary	The incidence of Treatment-emergent Adverse Events (TEAE) in subjects assigned to GMA301 compared with those assigned to placebo.		Through study completion (up to 22 weeks)
Secondary	Pharmacokinetics (Area under the serum concentration- time curve from time zero to the last measurable concentration)		Through study completion (up to 22 weeks)
Secondary	Comparison of GMA301 treatment effect at Week 12 versus baseline regarding the pulmonary vascular resistance (PVR) based on right heart catheterization (RHC)		Baseline to Week 12
Secondary	Comparing 6MWT distance		Baseline to Week 12